Adverse reactions are listed as follows by system organ class and frequency. Frequencies are defined as: very common (≥ 1/10);
common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
The frequency of adverse reactions identified from placebo-controlled clinical studies of sitagliptin monotherapy and post-marketing experience: See table.
Click on icon to see table/diagram/image